object
determin
efficaci
safeti
withhold
antimicrobi
children
cancer
fever
neutropenia
fn
demonstr
respiratori
viral
infect
method
prospect
multicentr
random
studi
children
present
fn
five
hospit
santiago
chile
evalu
admiss
diagnosi
bacteri
viral
pathogen
includ
pcrmicroarray
respiratori
virus
children
posit
respiratori
viru
neg
bacteri
pathogen
favour
evolut
h
antimicrobi
therapi
random
either
maintain
withhold
antimicrobi
primari
endpoint
percentag
episod
unev
resolut
secondari
endpoint
day
feverhospit
bacteri
infect
sepsi
admiss
paediatr
intens
care
unit
picu
death
result
total
children
fn
episod
recruit
juli
decemb
respiratori
viru
uniqu
identifi
microorgan
random
maintain
antimicrobi
withdraw
median
durat
antimicrobi
use
day
rang
day
versu
day
rang
day
similar
frequenc
unev
resolut
respect
signific
ci
p
similar
number
day
fever
versu
day
hospit
versu
bacteri
infect
throughout
episod
one
case
sepsi
requir
admiss
picu
group
maintain
antimicrobi
without
death
conclus
reduct
antimicrobi
children
fn
respiratori
viral
infect
base
clinic
microbiologicalmolecular
diagnost
criteria
favour
adopt
evidencebas
manag
strategi
popul
santolaya
cmi
children
cancer
expos
viral
bacteri
fungal
infect
especi
episod
fever
neutropenia
fn
episod
fn
chemotherapi
current
manag
within
hospit
broadspectrum
antimicrobi
therapi
recent
common
aetiolog
agent
report
fn
episod
occur
children
cancer
bacteri
fungal
pathogen
viral
infect
particularli
respiratori
virus
increasingli
recogn
signific
aetiolog
agent
fn
popul
respiratori
viral
infect
lead
caus
morbid
mortal
immunocompet
children
paediatr
patient
cancer
respiratori
virus
detect
episod
fn
previou
studi
determin
frequenc
clinic
outcom
respiratori
virusposit
fn
episod
respiratori
virus
common
agent
detect
clinic
outcom
episod
significantli
better
episod
singl
bacteri
infect
viralebacteri
coinfect
children
respiratori
viral
infect
fewer
day
hospit
lower
probabl
haemodynam
instabl
lower
rate
admiss
paediatr
intens
care
unit
picu
children
fn
research
effort
focus
manag
bacteri
fungal
infect
mainli
propos
model
risk
predict
invas
bacteri
fungal
infect
improv
molecular
diagnosi
infect
select
antimicrobi
manag
children
highrisk
lowrisk
fn
episod
contrast
increas
studi
bacteri
fungal
infect
popul
studi
viral
infect
scarc
recogn
research
gap
field
ration
approach
toward
manag
potenti
infect
children
cancer
fn
requir
comprehens
analysi
microbiolog
agent
involv
implement
systemat
studi
earli
detect
respiratori
viral
infect
children
cancer
fn
might
help
optim
manag
reduc
hospit
antimicrobi
use
studi
aim
determin
efficaci
safeti
withhold
antimicrobi
treatment
h
admiss
children
cancer
fn
demonstr
respiratori
viral
infect
favour
clinic
cours
juli
decemb
prospect
random
multicentr
governmentsponsor
studi
conduct
five
particip
hospit
santiago
chile
belong
nation
child
programm
antineoplast
drug
network
children
adolesc
cancer
year
age
admit
episod
fn
enrol
parent
child
sign
inform
consent
assent
older
year
age
children
haematopoiet
stem
cell
transplant
exclud
studi
approv
ethic
committe
particip
institut
children
evalu
admiss
character
febril
episod
establish
risk
invas
bacteri
infect
perform
common
protocol
diagnosi
bacteri
viral
pathogen
record
age
gender
type
cancer
type
date
last
chemotherapi
use
granulocyt
colonystimul
factor
use
antimicrobi
prophylaxi
use
central
venou
cathet
hour
fever
admiss
axillari
temperatur
blood
pressur
heart
rate
respiratori
rate
sign
symptom
indic
infecti
focusdespeci
respiratori
sign
symptom
haematolog
statu
absolut
neutrophil
count
anc
haemoglobin
level
platelet
count
biochem
test
quantit
c
reactiv
protein
crp
central
peripher
autom
blood
cultur
cultur
clinic
indic
molecularbas
evalu
respiratori
virus
initi
evalu
children
treat
follow
latin
american
consensu
ration
approach
children
fn
guidelin
manag
fn
children
cancer
briefli
children
hospit
lowrisk
fn
episod
treat
thirdgener
cephalosporin
ceftriaxon
wherea
children
high
risk
treat
antipseudomon
thirdgener
cephalosporin
ceftazidim
plu
amikacin
without
antigramposit
blactam
glycopeptid
antimicrobi
therapi
h
hospit
day
children
nasopharyng
sampl
posit
respiratori
viru
absenc
posit
bacteri
cultur
favour
clinic
evolut
subject
simpl
random
studi
coordin
blind
use
statist
softwar
graphpad
prism
version
graphpad
san
diego
ca
usa
two
group
mainten
antimicrobi
end
febril
episod
intervent
group
antimicrobi
withdrawn
accord
ethic
committe
requir
possibl
random
child
one
episod
fn
met
studi
criteria
reason
one
random
episod
fn
equival
one
random
patient
group
monitor
daili
clinic
laboratori
evolut
fever
resolut
anc
children
bacteri
pathogen
children
studi
gave
neg
result
continu
antimicrobi
manag
accord
current
standard
care
antimicrobi
withdraw
group
criteria
reinstal
antimicrobi
therapi
resurg
fever
clinic
worsen
new
clinic
andor
laboratori
find
suggest
bacteri
infect
one
blind
investig
evalu
case
discharg
decid
outcom
unev
without
access
inform
specif
intervent
child
see
definit
children
continu
antimicrobi
therapi
standard
durat
therapi
day
antimicrobi
stop
day
children
favour
evolut
least
full
day
without
fever
two
consecut
crp
valu
mgl
anc
criterion
stop
antimicrobi
therapi
primari
endpoint
group
maintain
antimicrobi
group
antimicrobi
withhold
number
episod
unev
resolut
secondari
endpoint
number
day
fever
b
number
day
hospit
c
percentag
episod
develop
demonstr
probabl
invas
bacteri
infect
reinstal
antimicrobi
therapi
e
sepsi
hospit
f
admiss
picu
g
death
laboratori
evalu
laboratori
test
haematolog
biochem
microbiolog
test
perform
hospit
accord
standard
techniqu
molecular
detect
respiratori
virus
detect
perform
nasopharyng
sampl
collect
children
time
admiss
flock
swab
brescia
itali
swab
insert
vial
contain
viral
transport
medium
utmrt
transport
central
laboratori
store
c
analysi
next
h
admiss
total
nucleic
acid
extract
easymag
nuclisen
biom
erieux
durham
nc
usa
test
respiratori
virus
influenza
b
c
parainfluenza
respiratori
syncyti
viru
rsv
b
rhinoviru
adenoviru
echoviru
human
bocaviru
coronaviru
human
metapneumovirus
b
multiplexpcr
lowdens
microarray
accord
manufactur
instruct
pneumovir
genomica
madrid
spain
definit
neutropenia
anc
b
fever
singl
axillari
temperatur
c
c
two
measur
separ
least
h
c
highrisk
fn
fn
episod
one
follow
factor
time
admiss
relaps
leukaemia
cancer
type
ii
hypotens
iii
quantit
crp
mgl
follow
two
factor
iv
day
last
chemotherapi
begin
fever
v
platelet
count
lowrisk
fn
fn
episod
without
mention
factor
e
episod
favour
evolut
h
antimicrobi
therapi
good
clinic
condit
subject
evalu
clinic
condit
attend
physician
temperatur
c
absenc
identifi
new
clinic
focu
crp
mgl
f
unev
resolut
favour
resolut
fn
episod
accord
random
intervent
without
chang
therapi
group
maintain
antimicrobi
without
reinstal
group
antimicrobi
withhold
g
demonstratedprob
invas
bacteri
infect
bacteraemia
isol
bacteria
normal
steril
site
clinic
sign
suggest
local
bacteri
infect
parenchym
involv
without
microbiolog
isol
h
sepsi
system
inflammatori
respons
syndrom
accompani
abnorm
tissu
perfus
caus
presumpt
bacteri
infect
without
microbiolog
confirm
respiratori
viral
infect
detect
least
one
respiratori
viru
nasopharyng
sampl
pcr
j
upperlow
respiratori
viral
infect
infect
respiratori
tract
clinic
affect
larynx
toward
proxim
beyond
larynx
plu
respiratori
viral
infect
respect
sampl
size
primari
endpoint
noninferior
studi
number
episod
unev
resolut
sampl
size
calcul
base
hypothesi
frequenc
occurr
unev
resolut
group
consid
unfavour
outcom
previous
report
popul
maximum
accept
differ
group
type
error
potenc
calcul
episod
requir
group
maintain
antimicrobi
therapi
antimicrobi
withhold
group
overal
capac
enrol
five
studi
site
estim
episod
per
year
enrol
estim
total
fn
episod
studi
period
categor
variabl
compar
chisquar
test
fisher
exact
test
depend
number
episod
per
comparison
group
continu
variabl
compar
two
group
accord
distribut
student
mannewhitney
u
test
risk
unev
resolut
evalu
expos
unexpos
group
calcul
respect
ci
statist
analys
perform
sigma
stat
program
systat
softwar
ca
usa
juli
decemb
total
episod
fn
evalu
five
hospit
particip
studi
episod
enrol
exclud
children
parent
refus
particip
episod
meet
inclus
criteria
incomplet
data
episod
enrol
evalu
bacteri
viral
infect
receiv
empir
antimicrobi
therapi
posit
nasopharyng
sampl
respiratori
virus
admiss
neg
bacteri
pathogen
fortyeight
hour
later
episod
met
criteria
random
random
current
antimicrobi
manag
antimicrobi
withhold
time
random
median
anc
mm
mainten
withhold
antimicrobi
group
respect
p
children
anc
group
p
episod
posit
respiratori
viru
neg
bacteri
pathogen
random
favour
evolut
h
antimicrobi
therapi
maintain
fever
crp
mgl
five
haemodynam
instabl
new
clinic
foci
random
adher
protocol
fig
tabl
describ
main
characterist
children
episod
fn
posit
respiratori
viral
infect
random
group
age
gender
type
cancer
characterist
similar
two
group
p
ns
less
children
group
receiv
prophylaxi
trimethoprimsulfamethoxazol
pneumocysti
jirovecii
eightyeight
episod
highrisk
fn
episod
random
respect
clinic
characterist
suggest
upperlow
respiratori
tract
infect
time
admiss
tabl
show
outcom
random
children
accord
intervent
expect
median
durat
antimicrobi
therapi
significantli
differ
children
maintain
day
interquartil
rang
iqr
day
compar
children
antimicrobi
withdrawn
day
iqr
day
p
percentag
episod
fn
unev
resolut
respect
p
ns
ci
p
day
fever
day
hospit
develop
demonstratedprob
invas
bacteri
infect
similar
among
group
death
occur
three
children
demonstratedprob
bacteri
infect
two
bacteraemia
caus
extend
spectrum
blactamaseposit
klebsiella
pneumonia
group
maintain
antimicrobi
one
case
cultureneg
sinus
antimicrobi
withhold
group
reinstal
antimicrobi
therapi
indic
four
children
four
acut
myeloid
leukaemia
admit
highrisk
fn
met
studi
criteria
upper
respiratori
viral
infect
four
case
antimicrobi
discontinu
children
good
clinic
condit
temperatur
c
crp
mgl
accord
protocol
three
present
fever
day
admiss
without
identifi
new
foci
clinic
deterior
crp
mgl
clinic
cours
favour
three
children
fever
declin
one
day
new
antimicrobi
therapi
absenc
bacteri
pathogen
detect
fourth
child
develop
fever
day
increas
crp
mgl
clinic
imag
find
suggest
sinus
requir
antimicrobi
therapi
child
develop
sepsi
admit
picu
discharg
diagnosi
probabl
invas
bacteri
infect
one
child
group
maintain
antimicrobi
develop
sepsi
admit
picu
girl
neuroblastoma
highrisk
fn
upper
respiratori
infect
day
random
afebril
crp
valu
mgl
day
present
fever
haemodynam
instabl
blood
cultur
obtain
day
posit
extend
spectrum
blactamaseposit
klebsiella
pneumonia
crp
valu
increas
mgl
admit
picu
receiv
antimicrobi
base
bacteri
isol
new
period
day
good
clinic
outcom
death
occur
among
random
children
studi
period
perform
separ
analysi
episod
random
accord
risk
statu
invas
bacteri
infect
determin
admiss
children
episod
lowrisk
fn
median
durat
antimicrobi
therapi
day
iqr
day
iqr
p
episod
unev
resolut
without
case
antimicrobi
reinstal
develop
sepsi
admiss
picu
episod
highrisk
fn
median
durat
antimicrobi
therapi
day
iqr
day
iqr
p
episod
unev
resolut
group
four
case
antimicrobi
reinstal
one
case
sepsi
admiss
picu
describ
previous
main
respiratori
virus
identifi
children
random
episod
fn
describ
tabl
overal
common
respiratori
viru
rhinoviru
follow
rsv
parainfluenza
viru
influenza
viru
differ
respiratori
virus
detect
sole
pathogen
onethird
children
cancer
admit
febril
neutropen
episod
almost
half
met
studi
criteria
favour
evolut
h
allow
random
overal
episod
antimicrobi
withdrawn
unev
resolut
previous
demonstr
possibl
appli
select
manag
propos
ambulatori
therapi
children
lowrisk
fn
defin
accord
follow
paramet
type
cancer
haemodynam
stabil
crp
valu
platelet
count
number
day
sinc
last
chemotherapi
studi
advanc
step
includ
possibl
stop
antimicrobi
therapi
h
admiss
children
posit
respiratori
viral
infect
neg
bacteri
infect
favour
clinic
cours
includ
episod
low
high
risk
invas
bacteri
infect
knowledg
epidemiolog
respiratori
viral
infect
immunocompromis
children
scarc
systemat
studi
aim
determin
clinic
impact
rsv
influenza
viru
parainfluenza
viru
adenoviru
picornavirus
common
aetiolog
agent
detect
popul
increas
detect
virus
highlight
relev
optim
viral
diagnosi
children
fn
children
cancer
highrisk
fn
requir
immedi
hospit
aggress
intraven
antimicrobi
treatment
observ
unev
resolut
random
fn
episod
despit
fact
classifi
high
risk
admiss
consid
data
systemat
evalu
respiratori
virus
time
hospit
admiss
could
help
establish
ration
treatment
select
group
patient
miedema
et
al
recent
report
safe
shorten
antimicrobi
treatment
h
select
mediumrisk
children
fn
antimicrobi
stop
episod
failur
observ
howev
highrisk
episod
includ
studi
approxim
episod
fn
present
seriou
bacteri
infect
therefor
extens
assess
multiplex
blood
respiratori
pcr
assay
could
increas
pathogen
detect
facilit
tailormad
therapi
reduc
unnecessari
antimicrobi
exposur
studi
limit
includ
intervent
doubl
blind
decid
conduct
doubleblind
studi
major
children
receiv
antimicrobi
therapi
use
central
venou
cathet
prefer
use
central
venou
cathet
children
antimicrobi
withheld
avoid
unnecessari
manipul
anoth
possibl
issu
children
random
cohort
respiratori
viru
detect
present
upper
lower
respiratori
tract
infect
time
admiss
although
posit
pcr
detect
alway
necessarili
relat
respiratori
diseas
major
children
studi
present
respiratori
symptom
suggest
role
respiratori
virus
detect
pcr
conclus
suggest
incorpor
molecular
respiratori
viral
studi
initi
evalu
children
cancer
episod
fn
reduct
antimicrobi
use
children
fn
demonstr
respiratori
viral
infect
base
stringent
clinic
microbiolog
molecular
diagnost
criteria
could
favour
adopt
evidencebas
ration
manag
strategi
popul
author
declar
conflict
interest
work
support
nation
fund
scientif
technolog
develop
fondecyt
chile
grant
number
twentythre
episod
viral
coinfect
twentyon
case
two
respiratori
virus
two
case
three
respiratori
virus
b
twentytwo
episod
viral
coinfecct
case
two
respiratori
virus
c
without
signific
differ
group
